Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Period	Debt/Equity
2022-12-31	0.07
2023-12-31	0.06
2024-12-31	0.05

	A	B	C	D
1	Symbol	Price	Change	Volume
2	APGE	$82.98	-0.36%	0.57M
3
4
5

Apogee Therapeutics Inc. (APGE) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Apogee Therapeutics Inc. Data in Excel

More APGE Financial Data